Exametazime
Active ingredient: Technetium Tc-99M Exametazime
In short: Drax Exametazime is indicated for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
What is Exametazime used for?
Drax Exametazime is indicated for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
Exametazime dosage
Technetium Tc 99m exametazime is a radioactive solution and should be handled with appropriate safety measures to minimize radiation exposure. During handling use waterproof gloves and effective shielding, including syringe shields .
Use strict aseptic procedures throughout preparation and handling.
Visually inspect the reconstituted technetium Tc 99m exametazime solution for particulate matter and discoloration prior to radiolabeling of white blood cells. Do not use the reconstituted solution if there is evidence of particulate matter or discoloration.
Follow the directions of drug preparation carefully to ensure efficient leukocytes labeling .
Measure patient dose with a suitable radioactivity calibration system immediately prior to administration.
Instruct patients to hydrate, after administration of technetium Tc 99m exametazime labeled white blood cells and void frequently to minimize radiation dose to the kidneys and bladder .
For an adult patient the recommended intravenous injection dose range for technetium Tc 99m exametazime labeled leukocytes is 259 - 925 Megabecquerels (MBq) [7-25 millicuries (mCi)].
Acquisition
Instruct patients to empty their bladder prior to imaging.
Obtain serial pelvic and abdominal images beginning at 0.5 – 1 hour post-injection and continue up to 4 hours.
Interpretation
Accumulation of radioactivity in bowel seen in early images [less than 4 hours] with increasing intensity and/or no evidence of changing location secondary to GI motility likely represents inflammatory bowel disease or infection. Radioactivity from hepatic excretion detected in the bowel 4 hours post-injection and changing in GI location on serial/subsequent images is indicative of normal GI transit
IMPORTANT
- Label all syringes and tubes used in this labeling procedure with the patient’s name and unique identification number.
Leukocyte Harvest and Separation
1. Draw 2 mL of Heparin and 8 mL of 6% Hydroxyethyl starch into a 60 mL plastic syringe.2. Withdraw approximately 40 mL whole blood from the patient into the syringe using a 19-gauge Butterfly needle infusion set. Close the syringe with a sterile hub.3. Gently mix the contents for 2 minutes.4. Clamp the syringe barrel to the ring stand in an upright (hub side up) position and tilt the syringe approximately 10-20 degrees from its position perpendicular to the bench.5. Allow the syringe to stand a minimum of 60 minutes until the red blood cells sediment and the supernatant looks clear.6. Using an infusion set, transfer the leukocyte-rich plasma (LRP), the supernatant, from the previous step, into a sterile, conical centrifuge tube marked "WBC" (white blood cell) and assure that only a minimum amount of red cells enter the centrifuge tube.7. …
How to take Exametazime — instructions & advice from the label
Administration Instructions:
Advise patients to hydrate after administration of technetium Tc 99m exametazime labeled leukocytes and to void frequently to minimize radiation dose .
Pregnancy
Advise pregnant women of the risk of fetal exposure to radiation doses if they undergo a radionuclide procedure .
Lactation
Advise lactating women that exposure of the infant to technetium Tc 99m through breast milk can be minimized if breastfeeding is interrupted when technetium Tc99m exametazime labeled leukocytes are administered. Advise a lactating woman to pump and discard breast milk for 12 to 24 hours based on injected dose .
Manufactured for:Jubilant DraxImage Inc., Kirkland, Quebec, Canada, H9H 4J4.
Art rev.: 1.0
Warnings & precautions
Do not take this medicine if: None.
Hypersensitivity reactions, including serious signs and symptoms of anaphylaxis, following administration of Tc 99m labeled leukocytes prepared using Tc 99m exametazime have been reported. Always have cardiopulmonary resuscitation equipment and personnel available and monitor all patients for hypersensitivity reactions.
The interpretation of images can be affected by the presence of other pathophysiological processes within and outside of the abdominal cavity such as: tumor, infarction, trauma, and other inflammatory conditions.
Technetium Tc 99m contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation reconstitution procedures to protect patients and health care workers from unintentional radiation exposure. Encourage patients to drink fluids and void as frequently as possible after administration .
Exametazime side effects
The following adverse reactions are described elsewhere in the labeling;
Hypersensitivity reactions .
The following adverse reactions associated with the use of technetium Tc 99m exametazime have been identified in clinical trials or post-marketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular: transient blood pressure increase
Skin and subcutaneous tissue disorders: rash, generalized erythema, urticaria, angioedema, pruritus.
General disorders and administration site conditions: facial edema, fever, asthenic conditions (e.g., malaise, fatigue).
Nervous system disorders: headache, dizziness, paraesthesia.
Vascular disorders: flushing.
Gastrointestinal disorders: nausea, vomiting.
About this medicine
Drax Exametazime (kit for the preparation of technetium Tc 99m exametazime for leukocyte labeling) prepares a radioactive diagnostic agent. Each single-dose vial contains a sterile, non-pyrogenic, lyophilized mixture of 0.5 mg exametazime, 7.6 mcg stannous chloride dihydrate (minimum stannous tin 0.6 mcg; maximum total stannous and stannic tin 4 mcg per vial) and 4.5 mg sodium chloride, sealed under nitrogen atmosphere with a rubber closure. The product contains no antimicrobial preservative.The chemical formula of exametazime is C13H28N4O2, with the following structural formula:
Prior to publication of the USAN, exametazime [also known as (RR,SS)-4.8-diaza-3,6,6,9-tetramethylundecane-2, 10-dione bisoxime] was known as hexamethylpropylene amine oxime (HM-PAO). The name HM-PAO appears in many publications.
When Tc 99m pertechnetate in Sodium Chloride Injection, USP (0.9%) is added to Drax Exametazime vial, a Tc 99m complex of exametazime is formed.
Tc 99m decays by isomeric transition with a physical half-life of 6 hours. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fa7811f9-2803-4126-8037-8f3e56462f9c. Read the full official label on DailyMed.